Our current lead product candidate RECCE® 327, is currently undergoing pre-clinical tests aimed at compiling data for our Investigational New Drug (IND) application to be submitted to the US Food & Drug Administration (FDA) and approval to start the first of a series of tests in humans.

We have a strong emerging pipeline of product candidates targeting a number of anti-bacteria and anti-viral applications. Pre-clinical studies are currently underway to establish the safety and efficacy of these compounds which are based on our core technology platform.


Sign up for news and updates

Receive news and information direct to your inbox.